Fig. 1From: Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responsesFlow chart showing the participants undergoing microbiome analysis. Overall, 99 patients with RA (who had been treated for at least a year) and 30 healthy participants were enrolled in the study. A tofacitinib user and 4 patients with malignancy were excluded from the final analysis. Patients with RA were divided according to the use of biological DMARDs, as well as disease activity (remission: DAS28 < 2.6, low disease activity: 2.6 ≤ DAS28 ≤ 3.2, moderate disease activity: 3.2 < DAS28 ≤ 5.1, high disease activity: DAS28 > 5.1), at the time of stool collection. In patients with moderate-to-high disease activity, therapeutic changes were recorded, and the response after 6 months was followed-up. bDMARDs, biological disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic DMARDs; F/U, follow-upBack to article page